abdominal gasNo significant difference
Diffuse abdominal pain, abdominal gas, taste disturbance, urticaria, nausea symptoms were similar in both groups.
from: Efficacy and Safety of Saccharomyces boulardii in the 14‐day Triple Anti‐Helicobacter pylodiarrheaNo significant difference14.5% vs 30.6%
Nine (14.5%) patients in the treatment group and 19 (30.6%) patients in the placebo group experienced diarrhea (p < .05).
from: Efficacy and Safety of Saccharomyces boulardii in the 14‐day Triple Anti‐Helicobacter pylodiffuse abdominal painNo significant difference
Diffuse abdominal pain, abdominal gas, taste disturbance, urticaria, nausea symptoms were similar in both groups.
from: Efficacy and Safety of Saccharomyces boulardii in the 14‐day Triple Anti‐Helicobacter pyloepigastric discomfortNo significant difference14.5% vs 43.5%
Epigastric discomfort was more frequent in the control group [9 (14.5%) versus 27 (43.5%), respectively (p < .01)].
from: Efficacy and Safety of Saccharomyces boulardii in the 14‐day Triple Anti‐Helicobacter pylonauseaNo significant difference
Diffuse abdominal pain, abdominal gas, taste disturbance, urticaria, nausea symptoms were similar in both groups.
from: Efficacy and Safety of Saccharomyces boulardii in the 14‐day Triple Anti‐Helicobacter pylotaste disturbanceNo significant difference
Diffuse abdominal pain, abdominal gas, taste disturbance, urticaria, nausea symptoms were similar in both groups.
from: Efficacy and Safety of Saccharomyces boulardii in the 14‐day Triple Anti‐Helicobacter pylourticariaNo significant difference
Diffuse abdominal pain, abdominal gas, taste disturbance, urticaria, nausea symptoms were similar in both groups.
from: Efficacy and Safety of Saccharomyces boulardii in the 14‐day Triple Anti‐Helicobacter pylo